Inorganic nanomaterials activate the cGAS-STING pathway for tumor treatment
Youdong Chen1, Qian Li2, Jinhua Zhou3
1School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Taipa, 999078, Macau SAR, China; Macao Institute of Materials Science and Engineering, Macau University of Science and Technology, Taipa 999078, Macau SAR, China; Institute of Functional Nano & Soft Materials (FUNSOM), Biomedical-Basic Research-Center (BBRC) of Jiangsu Province, Soochow University, Suzhou 215123, China.
Pharmacology & Therapeutics
|July 24, 2026
Summary
Inorganic nanomaterials offer a novel approach to cancer immunotherapy by enhancing the stimulator of interferon genes (STING) pathway activation. These materials improve STING agonist delivery and potentiate immune responses for better cancer treatment.
Area of Science:
- Oncology
- Immunology
- Materials Science
Background:
- The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is crucial for DNA-triggered innate immunity in cancer.
- Clinical use of STING agonists is limited by poor stability, delivery issues, and systemic inflammation.
Purpose of the Study:
- To review the application of inorganic nanomaterials for enhancing cGAS-STING pathway activation in cancer immunotherapy.
- To explore design strategies for nanomaterial-based STING agonists and their synergistic therapeutic integration.
Main Methods:
- Systematic review of inorganic nanomaterials for STING pathway modulation.
- Analysis of nanomaterial properties for agonist protection, controlled release, and synergistic effects.
- Discussion of integration with therapies like radiosensitization and immunogenic cell death induction.
Main Results:
- Inorganic nanomaterials enable precise delivery and controlled release of STING agonists.
- These materials can independently activate STING and synergistically enhance its activation.
- Nanomaterials facilitate integration with other cancer therapies, creating amplification immune circuits.
Conclusions:
- Inorganic nanomaterials offer a versatile platform for STING-targeted cancer immunotherapy.
- They act as carriers, adjuvants, and inducers, improving both efficacy and safety.
- This approach presents a new paradigm for developing advanced cancer immunotherapies.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...